Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 8/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110579 | 0.87 | KCNK3 (0.46) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17328152 | 0.86 | F12 (0.47) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17317851 | 0.86 | KCNK3 (0.48) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17317715 | 0.86 | KCNK3 (0.46) | KCNK3 | |
| SCHEMBL17317679 | 0.85 | KCNK3 (0.49) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17317814 | 0.85 | KCNK3 (0.45) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17317618 | 0.85 | KCNK3 (0.45) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL19110576 | 0.85 | KCNK3 (0.45) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17317790 | 0.85 | KCNK3 (0.44) | KCNK3KDM1AHDAC1HDAC6PTGER4 | |
| SCHEMBL17317641 | 0.85 | KCNK3 (0.44) | KCNK3KDM1AHDAC1HDAC6PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885KDM1A 1424/4885HDAC1 996/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885KDM1A 1423/4885HDAC1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.